Skip to main content

Premenstrual Dysphoric Disorder

  • Reference work entry
  • First Online:
  • 27 Accesses

Synonyms

Premenstrual syndrome (PMS)

Definition

Premenstrual dysphoric disorder (PMDD) is defined in the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric Association 2013) as a depressive disorder typified by marked mood changes (i.e., anxiety, depression, irritability, affective lability) as well as behavioral and physical symptoms (i.e., anhedonia, difficulty concentrating, lethargy, dyssomnia), which occur immediately prior to menses, improve during menses, and become minimal or absent immediately after menses. It is critical that PMDD is differentiated from the exacerbation of other mental disorders around the time of menses. For example, PMDD has a short and cyclical course compared to the chronicity observed in major depressive disorder. Although PMDD and PMS are often used interchangeably, they are different; the latter is considered less severe and does not require the presence of affective symptoms.

Categorization

PMDD is classified...

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   899.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   1,099.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References and Readings

  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®). Washington, DC: American Psychiatric Association.

    Book  Google Scholar 

  • Martinez, P. E., Rubinow, D. R., Nieman, L. K., Koziol, D. E., Morrow, A. L., Schiller, C. E., ... & Schmidt, P. J. (2016). 5α-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology, 41(4), 1093–1102.

    Article  PubMed Central  Google Scholar 

  • Pearlstein, T. (2016). Treatment of premenstrual dysphoric disorder: Therapeutic challenges. Expert Review of Clinical Pharmacology, 9(4), 493–496.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Amma A. Agyemang .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Agyemang, A.A. (2018). Premenstrual Dysphoric Disorder. In: Kreutzer, J.S., DeLuca, J., Caplan, B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, Cham. https://doi.org/10.1007/978-3-319-57111-9_9173

Download citation

Publish with us

Policies and ethics